<DOC>
	<DOCNO>NCT01851174</DOCNO>
	<brief_summary>To determine whether occurrence adverse event decrease move bi-weekly schedule gemcitabine plus nab-Pacitaxel treatment unresectable/metastatic pancreatic cancer .</brief_summary>
	<brief_title>Study Evaluate Bi-weekly Dosing Gemcitabine Plus Nab-Paclitaxel Treat Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>This study help determine whether occurrence adverse event decrease move bi-weekly , opposed weekly , dose schedule gemcitabine plus nab-Pacitaxel treatment unresectable/metastatic pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patients must histologicallyproven unresectable/metastatic pancreatic adenocarcinoma . 2 . Patient one radiographically measurable tumor . 3 . Patients may receive prior adjuvant chemotherapy radiation therapy ( RT ) . 4 . Age ≥ 18 year . 5 . Patient must read , understood , provide write informed consent HIPAA authorization full explanation nature study . 6 . ECOG performance status 0 2 expect survival least 3 month . 7 . Acceptable hematological parameter within 2 week commence study therapy follow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Hemoglobin ( Hgb ) ≥ 9g/dl 8 . Patients adequate organ function measure : A. Cardiac : American Heart Association Class I : Patients cardiac disease without result limitation physical activity . Ordinary physical activity cause undue fatigue , palpitation , dyspnea , anginal pain . B. Hepatic : Bilirubin ≤ 2.0 mg/ ALT AST ≤ 1.5x upper limit normal . C. Renal : Creatinine ≤ 1.5 mg/dl chronic kidney disease . 9 . Women must meet one follow criterion : Postmenopausal least one year Surgically incapable childbearing Utilizing reliable form contraception duration study participation . Women childbearing potential must negative serum βHCG within 7 day study drug administration . 1 . Previous use nabPaclitaxel treatment pancreatic cancer either monotherapy combination neoadjuvant , adjuvant , metastatic setting . 2 . Previous use chemotherapy radiation therapy metastatic disease . 3 . Patient known brain metastasis , unless previously treat wellcontrolled least 3 month ( define clinically stable , edema , steroid stable 2 scan least 4 week apart ) . 4 . Other significant active chronic infection . 5 . History active malignancy exclude basal squamous cell carcinoma skin cervical intraepithelial neoplasia . 6 . Pregnant nursing female . 7 . Patient serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise patient 's safety study data integrity . 8 . Major surgery , diagnostic surgery within 4 week study entry . 9 . Patient require legal authorized representative consenting .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>